Skip to main content
  • Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer

    Collaboration Combines Merck's Leadership in Immuno-Oncology with Moderna's Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities

  • Moderna and the Bill & Melinda Gates Foundation Create Global Health Partnership

    “Moderna’s research has considerable potential for the development of an effective prevention intervention for HIV, and potentially other infectious diseases that disproportionately affect the world’s poorest people.”

    Dr. Trevor Mundel, president of Global Health at the Bill & Melinda Gates Foundation

  • AstraZeneca and Moderna Therapeutics Announce New Collaboration to Co-Develop and Co-Commercialize Immuno-Oncology mRNA Therapeutics™

    “We’re pleased to be expanding our relationship with Moderna with this new collaboration, to advance the potential of pioneering messenger RNA technology in developing game-changing new treatments for cancer patients.”

    Dr. Pascal Soriot, CEO of AstraZeneca

  • Moderna Licenses New Vaccine Candidates to Merck

    Ongoing collaboration is yielding rapid progress; first vaccine candidate anticipated to enter clinic in 2016

  • Moderna has been selected as a 2015 Top Employer by Science magazine.

Our Mission

Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.